B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response.
about
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports projectAnti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients.Use of rituximab in the treatment of refractory systemic lupus erythematosus: Singapore experience.Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature.Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus.Targeting B cells with biologics in systemic lupus erythematosus.Distinct in vitro binding properties of the anti-CD20 small modular immunopharmaceutical 2LM20-4 result in profound and sustained in vivo potency in cynomolgus monkeys.Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial.Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID).Lipid-antigen presentation by CD1d(+) B cells is essential for the maintenance of invariant natural killer T cellsContemporary treatment of systemic lupus erythematosus: an update for clinicians.Taming lupus-a new understanding of pathogenesis is leading to clinical advances.Autoreactive IgG memory antibodies in patients with systemic lupus erythematosus arise from nonreactive and polyreactive precursors.HM71224, a novel Bruton's tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritisB cell modulation in rheumatologySystemic lupus erythematosus: pharmacological developments and recommendations for a therapeutic strategy.Targeting of the immune system in systemic lupus erythematosus.Treating patients with lupus with B-cell depletion.Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets.Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases.Translational Mini-Review Series on B Cell-Directed Therapies: B cell-directed therapy for autoimmune diseases.Translational Mini-Review Series on B Cell-Directed Therapies: The pathogenic role of B cells in autoantibody-associated autoimmune diseases--lessons from B cell-depletion therapy.Monoclonal Antibodies for Systemic Lupus Erythematosus (SLE).B cells as under-appreciated mediators of non-auto-immune inflammatory disease.Rituximab therapy in lupus nephritis: current clinical evidence.Alternative therapies: what role do they have in the management of lupus?Anticytokine therapy in systemic lupus erythematosus.Long-lived autoreactive plasma cells drive persistent autoimmune inflammation.State of the union between metabolism and the immune system in type 2 diabetes.Translational Mini-Review Series on B cell subsets in disease. Transitional B cells in systemic lupus erythematosus and Sjögren's syndrome: clinical implications and effects of B cell-targeted therapies.The link between VLA-4 and JC virus reactivation.B-cell targeted therapy in systemic lupus erythematosus: potential of rituximab.B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design.Rituximab biosimilars.Role and regulation of CD1d in normal and pathological B cells.Efficacy and safety of rituximab in rheumatic diseases.Improving B-cell depletion in systemic lupus erythematosus and rheumatoid arthritis.Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.Repopulation of B-lymphocytes with restricted gene expression using haematopoietic stem cells engineered with lentiviral vectors.Longer duration of B cell depletion is associated with better outcome.
P2860
Q33383576-C557F585-2A6F-48B4-BA66-7A00B524B368Q33387348-BC252C6B-A142-4A41-A2CB-6DD24C809DCCQ33388044-F6522506-8B60-48B0-AC10-F8E1E3EA66BEQ33407247-09A0D6B6-2418-41E5-AA85-9317E20D6FF9Q34063315-035F7749-B9A1-4740-BAA9-5234BADA7CD4Q34232326-50B8D6C6-83E8-414A-9C57-89207FE38D08Q34979203-77C8DD41-29BD-4FF2-AD37-F60D67D7BE71Q35030581-CDA7C9E8-FC66-4058-8C61-56C7A5ED0163Q35557832-84A6FCF8-6E86-4918-B792-DBB0F35100FAQ36081961-72E5E98D-ACD9-4205-9420-889CDB6773E0Q36443689-3FFC7F2B-63E2-484B-AED9-A3799AD4A02EQ36712941-FA08583D-74E4-4D86-AA0D-266D1A0CC16EQ36775342-8613BCD8-7D0D-4256-B050-2560342C4EBDQ36810546-3AD0D0BA-75FB-45D5-8B7F-EDBF30486164Q36878215-8DBFE23A-C757-4281-B29F-3EBCD2EBDA8FQ37038984-DAB1EFF5-5834-4728-A020-85996FA1AA8BQ37060593-E4A84819-485B-4F85-AB60-BA5C36933ABBQ37168014-9D308F54-5D2E-4728-87D0-8E35861D475EQ37436035-8CD71E68-F970-48EE-A940-92F599A4024AQ37541561-1F350D04-8001-4FB7-AE51-0852BBFDAB18Q37552017-564A7069-C20A-4FF2-B202-9CB6E8A01260Q37552019-06B8E68E-1B71-40E5-8C8B-0E98EA45B9A9Q37709460-D1C440C7-81BA-4A56-B4C2-3B8B7C66B5BEQ37728724-F96FE113-6B68-4254-B300-FC0C3B723084Q37737138-0C3E3852-ADCF-4E02-AA1E-BBED44EBEEBEQ37800300-8F18F4CB-6595-4B76-9726-8EFE9578BF09Q37800306-297F6DA9-34EA-4F14-8A53-B92A43AAE812Q37833902-538658AD-81B0-4702-972C-9B20B49DF0E1Q37851349-E40EEEFA-DC85-4EC6-ABEF-2E182D2D8BF2Q37963474-249F7E91-DADD-46D2-A281-96AC6BA3E752Q37965603-3CAC4C26-3B1E-45BC-BD28-D3A18B7520DEQ38051302-82363E34-CC6A-4289-8820-F0AE84747BE9Q38097129-768E30AE-EA74-435A-AB50-798AFEDD7161Q38100232-E3FF7C9E-89CD-4F9D-837A-191A808DC45FQ38266215-E84C8E68-1DFE-43D4-8F02-0DD4E2593082Q38353577-D43E8776-E126-40C4-BA2E-76554AE13E7EQ38408710-2765FDDD-43A2-49D5-9F55-B5E77292086CQ38466691-BD211C67-4CEC-43A9-A188-BB6E9C23BD7EQ38477522-A3E2BDE7-CA62-4652-AE7C-8FF9141BA36EQ38516182-CA443375-2691-4947-ABEB-826EE4D10309
P2860
B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
B cell depletion therapy in sy ...... up and predictors of response.
@ast
B cell depletion therapy in sy ...... up and predictors of response.
@en
type
label
B cell depletion therapy in sy ...... up and predictors of response.
@ast
B cell depletion therapy in sy ...... up and predictors of response.
@en
prefLabel
B cell depletion therapy in sy ...... up and predictors of response.
@ast
B cell depletion therapy in sy ...... up and predictors of response.
@en
P2093
P2860
P356
P1476
B cell depletion therapy in sy ...... up and predictors of response.
@en
P2093
Geraldine Cambridge
Jonathan C W Edwards
Kristine P Ng
Maria J Leandro
Michael Ehrenstein
P2860
P304
P356
10.1136/ARD.2006.067124
P407
P577
2007-04-05T00:00:00Z